Image

Acceptability of Simultaneous Screening for Viral Hepatitis B, C and HIV Among Drug Users in Non-conventional Structures

Acceptability of Simultaneous Screening for Viral Hepatitis B, C and HIV Among Drug Users in Non-conventional Structures

Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

The principle is to propose dedicated monthly screening days bringing together the health personnel involved (hepatologist, addictologist, nurse in charge of the program, addictology nurse and social worker) and to propose appropriate management for each situation assessed.

Description

  1. Information on screening, the days are announced by :
    • Mailing to health professionals in the Haute-Vienne Department,
    • Announcement to the different professional orders concerned (doctors, pharmacists, midwives, nurses, etc.),
    • Flyers and posters in health care facilities,
    • Distribution in the AddictLim network newsletter (pharmacists, nurses, social workers members),
    • Various: Liaison team, health delegate of the network, intranet site of the hospital, CCAS, AMPA, day care centers. 2. Conduct of a SCANVIR day in the non-conventional structure " Hors les murs " :

Each patient presenting during the screening day will have an individualized welcome.

Addictological and hepatological data will be collected throughout the process by the various workers on the individual Scanvir form (attached).

  1. The patient accepts one or more of the examinations proposed as part of the routine care. After information, he/she does not object to the collection of his/her personal data.
  2. One or more TRODs and a FibroScan® are performed by the nurse in charge of the care pathway and/or the facility.
  3. Performing, by the biologist or the authorized person, the delocalized PCR in case of positive HCV TROD
  4. Consultation with the hepatologist, who gives the results of the TROD and FibroScan® in a closed and dedicated place where the confidentiality of exchanges is guaranteed.
  5. A written document with the results of the TROD and FibroScan® and GeneXpert is given to the patient.

Method for routine management of patients according to results :

  1. HCV HBV HIV TROD are negative and FibroScan® > 7.1 KPa:

The patient meets directly with the hepatologist to screen for risk factors for chronic liver disease (alcohol, medications ...).

2. The HCV HBV HIV TROD are negative and the FibroScan ® < 7.1 KPa :

The nurse at the facility reviews with the patient the modes of transmission of the viruses and discusses with him/her risk reduction and harm reduction and what to do in case of recent exposure.

3. Positive HCV TROD:

The hepatologist offers to do an immediate and on-site HCV RNA by delocalized PCR (GeneXpert). If the HCV RNA is positive, HCV treatment is started immediately (excluding comorbidity). An appointment is proposed 3 months after treatment to control the cure by delocalized PCR on site (RVS12)

4. HIV or HBV TROD positivity:

The hepatologist proposes to do immediately and on site a complete blood test (HIV serology, HBV serologies (HBsAg, HBcAb, HBsAb) by the nurse present, assesses other risk factors and schedules an appointment for the results and management.

For all situations, a prevention action to reduce the risks of transmission of HCV and HBV will be carried out at the same time.

An anti-viral B vaccination may be offered.

Eligibility

Inclusion Criteria:

  • Adult 18 and over
  • Patient frequenting an unconventional structure "outside the walls" or referred by a professional in the care sector
  • Patient who agreed to participate to the research

Exclusion Criteria:

  • Patient doesn't agree to participate to the research

Study details
    Hepatitis C
    Transmission
    Intravenous Drug Abuser
    Addiction
    Alcohol
    Addiction Opiate
    Hepatitis C Virus Infection
    Response to Therapy of

NCT05361603

University Hospital, Limoges

26 January 2024

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.